Phase I study of bortezomib in refractory or relapsed acute leukemias.
Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, Garcia-Manero G, McConkey D, Ruiz SL, Guerciolini R, Wright J, Kantarjian H.
Cortes J, et al.
Clin Cancer Res. 2004 May 15;10(10):3371-6. doi: 10.1158/1078-0432.CCR-03-0508.
Clin Cancer Res. 2004.
PMID: 15161691
Clinical Trial.